Value Investors: 1 Global Cannabis Stock to Buy

As the company’s supply chain grows, Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) continues to expand the company’s portfolio of cannabis products for the existing markets in Canada.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

Cronos Group (TSX:CRON)(NASDAQ:CRON) is an innovative global cannabinoid (CBD) company with international production and distribution across five continents. Cronos Group builds disruptive intellectual property by advancing cannabis research, technology, and product development. The company is in the process of building an iconic brand portfolio that responsibly elevates the consumer experience.

In the United States, Cronos markets and distributes solely U.S. hemp-derived supplements and cosmetic products through e-commerce, retail and hospitality channels. In Canada, the company sells a variety of cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under the company’s wellness platform. In addition, dried cannabis and cannabis oils are currently exported for sale to Australia, Germany, and Israel.

Reputable wellness and adult-use brands

The company currently distribute products for the Canadian and non-U.S. international medical cannabis markets. Through the company’s global wellness platform, Cronos produces high-quality cannabis and cannabis products and is focused on building and shaping the global cannabis wellness market and promoting a holistic approach to wellness. The brand’s goal is to improve the lives of others one client at a time.

The company’s premium positioned brand is focused on creating crafted experiences. Cronos’s brands are geared towards a wide range of consumers who are looking for entertainment and fun ways to enhance activities. Cronos also owns lighthearted and playful brands that are focused on offering products that bring friends together and make experiences more enjoyable.

High-quality products

The company develops a preeminent U.S. hemp-derived CBD brand in the U.S. for the adult consumer goods market. Cronos focuses on high-quality U.S. hemp-derived personal care products that are distributed online to approximately 900 premium stores and retail channels.

Cronos recently launched a U.S. hemp-derived CBD brand in the United States. The product stems from the belief that well-being can lead to a better world that’s full of positivity and possibility. It is a belief that extends beyond the products and into everything the brand seeks to do and stand for. The brand intends to distribute products through the mass market focused retail channel in the U.S. in the future.

Diversified global network

Cronos has developed a diversified global sales and distribution network by leveraging established partners for the company’s scale, sales force and market expertise. The company has also built a distribution footprint in Canada through the direct-to-client medical market and the adult-use market, as well as a distribution footprint for hemp-derived consumer products in the U.S. through e-commerce, retail, and hospitality channels.

The company plans to use resources to capitalize on market demand and to further create and scale U.S. hemp-derived consumer products and brands. Cronos intends to access the U.S. mass market focused retail channel in the future. The company currently sells dried cannabis and cannabis extracts directly to clients through Cronos’s wellness platform. Clients are typically sourced through physician and clinic referrals or word-of-mouth recommendations from existing clients.

As the company’s supply chain grows, Cronos continues to expand the company’s portfolio of cannabis products for the existing markets in Canada.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »